Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-15 · accession 0001209191-23-010774 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-17 | 2023-02-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $8.44 | -746 | 189.1K | -0.4% | -$6,296 |
| DM | 2023-02-17 | 2023-02-15+ | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $8.35 | -9,254 | 189.8K | -5% | -$77.2K |
| D | 2023-02-17 | 2023-02-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +7,486 | 197.3K | +4% | +$16.6K |
| D | 2023-02-17 | 2023-02-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $0.00 | +7,486 | 629.5K | +1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-15 | F | D | 746 | $8.44 | 189,100 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-02-16 | S | D | 1,768 | $8.42 | 187,332 | D | — | — | |
| 3 | Common | Class A Common Stock | 2023-02-15 | S | D | 7,486 | $8.33 | 189,846 | D | — | — | |
| 4 | Common | Class A Common Stock | 2023-02-15 | M | A | 7,486 | $2.22 | 197,332 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-02-15 | M | A | 7,486 | $0.00 | 629,469 | D | $2.22 · — to 2030-03-03 | 7,486 Class A Common Stock | (F4) One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. |